Investing.com - Financial Markets Worldwide
⌛ Did you miss ProPicks’ 13% gains in May? Subscribe now & catch June’s top AI-picked stocks early.Unlock Stocks

New studies support functional cure of ContraVir's HBV candidate CRV431; shares ahead 8% premarket

Published 04/04/2017, 08:05 AM
New studies support functional cure of ContraVir's HBV candidate CRV431; shares ahead 8% premarket
GILD
-
HEPA
-
  • ContraVir Pharmaceuticals (NASDAQ:CTRV) is up 8% premarket on light volume in response to its announcement of new study data performed at the Scripps Research Institute that clarify the mechanism of action of CRV431, one of the company's candidates for the functional cure of hepatitis B virus (HBV) infection.
  • Results show that CRV431 blocks the interaction between hepatitis B surface antigen (HBsAg) and a key cellular protein called cyclophilin A. High levels of HBsAg is a predictor of disease progression leading to liver fibrosis, cirrhosis and cancer.
  • ContraVir's "functional cure" strategy for chronic HBV infection is based on combining drugs with complementary mechanisms of action. TXL (tenofovir exalidex prodrug), for example, works by lowering infectious virus in the blood. CRV431 complements TXL's activity by targeting HBsAg, possibly increasing the likelihood that the patient's immune system can kill the virus.
  • Phase 2-stage TXL is a prodrug of Gilead Sciences' (NASDAQ:GILD) VIREAD (tenofovir disoproxil fumarate). CRV431 is a next-generation cyclophilin inhibitor.

Original article

Latest comments

Loading next article…
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.